Skip to main content
Erschienen in: Clinical Pharmacokinetics 7/2015

01.07.2015 | Original Research Article

Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement

verfasst von: Salmaan Kanji, Meghan Hayes, Adam Ling, Larissa Shamseer, Clarence Chant, David J. Edwards, Scott Edwards, Mary H. H. Ensom, David R. Foster, Brian Hardy, Tyree H. Kiser, Charles la Porte, Jason A. Roberts, Rob Shulman, Scott Walker, Sheryl Zelenitsky, David Moher

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Transparent reporting of all research is essential for assessing the validity of any study. Reporting guidelines are available and endorsed for many types of research but are lacking for clinical pharmacokinetic studies. Such tools promote the consistent reporting of a minimal set of information for end users, and facilitate knowledge translation of research. The objective of this study was to create a guideline to assist in the transparent and complete reporting of clinical pharmacokinetic studies.

Methods

Preliminary content to be considered was identified from a systematic search of the literature and regulatory documents. Stakeholders were identified to participate in a modified Delphi exercise and a virtual meeting to generate consensus for items considered essential in the reporting of clinical pharmacokinetic studies. The proposed checklist was pilot tested on 100 recently published clinical pharmacokinetic studies. Overall and ite mized compliance with the proposed guidance was determined for each study.

Results

Sixty-eight stakeholders from nine countries consented to participate. Four rounds of a modified Delphi survey and a series of small virtual meetings were required to generate consensus for a 24-item checklist considered to be essential to the reporting of clinical pharmacokinetic studies. When applied to the 100 most recently published clinical pharmacokinetic studies, 45 were determined to be compliant with at least 80 % of the checklist items. Explanatory text was prepared using examples of compliant reporting from these and other relevant studies.

Conclusions

The reader’s ability to judge the validity of pharmacokinetic research can be greatly compromised by the incomplete reporting of study information. Using consensus methods, we have developed a tool to guide transparent and accurate reporting of clinical pharmacokinetic studies. Endorsement and implementation of these guidelines by researchers, clinicians and journals would promote more consistent reporting of these studies and allow for better assessment of utility for clinical applications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Upton D, Upton P. Knowledge and use of evidence-based practice of GPs and hospital doctors. J Eval Clin Pract. 2006;12:376–84.PubMedCrossRef Upton D, Upton P. Knowledge and use of evidence-based practice of GPs and hospital doctors. J Eval Clin Pract. 2006;12:376–84.PubMedCrossRef
2.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–32.PubMedCrossRef Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–32.PubMedCrossRef
4.
Zurück zum Zitat Rowland M, Tozer T. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. USA: Lippincott Williams and Wilkins; 2010. Rowland M, Tozer T. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. USA: Lippincott Williams and Wilkins; 2010.
5.
Zurück zum Zitat Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother. 2009;64:929–37.PubMedCrossRef Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother. 2009;64:929–37.PubMedCrossRef
12.
Zurück zum Zitat Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:1–4, 1–88. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:1–4, 1–88.
13.
Zurück zum Zitat Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm. 1996;24:245–63.PubMedCrossRef Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm. 1996;24:245–63.PubMedCrossRef
14.
Zurück zum Zitat Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci. 1983;72:1103–27.PubMedCrossRef Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci. 1983;72:1103–27.PubMedCrossRef
15.
Zurück zum Zitat Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207–46.PubMedCrossRef Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207–46.PubMedCrossRef
16.
Zurück zum Zitat Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46:221–34.PubMedCentralPubMedCrossRef Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46:221–34.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol. 2007;64:603–12.PubMedCentralPubMedCrossRef Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol. 2007;64:603–12.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.PubMedCrossRef
19.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.PubMedCrossRef Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.PubMedCrossRef
20.
Zurück zum Zitat Diamandopoulos A, Goudas P, Arvanitis A. Comparison of estimated creatinine clearance among five formulae (Cockroft–Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24 hours-urine-collection creatinine clearance. Hippokratia. 2010;14:98–104.PubMedCentralPubMed Diamandopoulos A, Goudas P, Arvanitis A. Comparison of estimated creatinine clearance among five formulae (Cockroft–Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24 hours-urine-collection creatinine clearance. Hippokratia. 2010;14:98–104.PubMedCentralPubMed
21.
22.
Zurück zum Zitat Ette EI, Sun H, Ludden TM. Ignorability and parameter estimation in longitudinal pharmacokinetic studies. J Clin Pharmacol. 1998;38:221–6.PubMedCrossRef Ette EI, Sun H, Ludden TM. Ignorability and parameter estimation in longitudinal pharmacokinetic studies. J Clin Pharmacol. 1998;38:221–6.PubMedCrossRef
23.
Zurück zum Zitat Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J. 2012;14:601–11.PubMedCentralPubMedCrossRef Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J. 2012;14:601–11.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014;42:1174–9.PubMedCrossRef Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014;42:1174–9.PubMedCrossRef
25.
Zurück zum Zitat Ritschel WA. Bioavailability/bioequivalence of modified release drug delivery systems: which pharmacokinetic parameters to determine, single or multiple dose studies, pretests, conditions and other aspects. Methods Find Exp Clin Pharmacol. 1992;14:469–82.PubMed Ritschel WA. Bioavailability/bioequivalence of modified release drug delivery systems: which pharmacokinetic parameters to determine, single or multiple dose studies, pretests, conditions and other aspects. Methods Find Exp Clin Pharmacol. 1992;14:469–82.PubMed
26.
Zurück zum Zitat Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921–8.PubMedCrossRef Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921–8.PubMedCrossRef
Metadaten
Titel
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
verfasst von
Salmaan Kanji
Meghan Hayes
Adam Ling
Larissa Shamseer
Clarence Chant
David J. Edwards
Scott Edwards
Mary H. H. Ensom
David R. Foster
Brian Hardy
Tyree H. Kiser
Charles la Porte
Jason A. Roberts
Rob Shulman
Scott Walker
Sheryl Zelenitsky
David Moher
Publikationsdatum
01.07.2015
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 7/2015
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0236-8

Weitere Artikel der Ausgabe 7/2015

Clinical Pharmacokinetics 7/2015 Zur Ausgabe